#-supreme-cart-cta-contact-block-6-6{oxy-supreme-cart-cta-contact-block-use-global:false}#-supreme-cart-trust-credibility-5-6{primary-logos-data:[{"image":"https:\/\/communitycart.org\/wp-content\/uploads\/2026\/08\/Client-logo.svg","alt":"","url":""},{"image":"https:\/\/communitycart.org\/wp-content\/uploads\/2026\/08\/Client-logo.svg","alt":"","url":""}];secondary-logos-data:[{"image":"https://communitycart.org/wp-content/uploads/2026/10/BMS-Logo.png","alt":"Bristol Myers Squibb","url":""},{"image":"https://communitycart.org/wp-content/uploads/2026/09/Kite-Color-Logo-PNG.png","alt":"Kite a Gilead Company","url":""},{"image":"https://communitycart.org/wp-content/uploads/2026/09/LEGEND-logo.png","alt":"Legend Biotech","url":""},{"image":"https://communitycart.org/wp-content/uploads/2026/09/InspiroGene_Logo.png","alt":"InspiroGene by McKesson","url":""}]}#-supreme-cart-who-this-is-for-3-6{cards-data:[{"icon":"https:\/\/communitycart.org\/wp-content\/uploads\/2026\/08\/Benefit.svg","title":"Hospital with an existing oncology program","description":"Adding cell therapy to services you already run."},{"icon":"https:\/\/communitycart.org\/wp-content\/uploads\/2026\/08\/FDA.png","title":"Community oncology outpatient practice","description":"Treating outpatient,close to where patients live."},{"icon":"https:\/\/communitycart.org\/wp-content\/uploads\/2026\/08\/Cell-Gene-Therapy-Sector-Data-and-Sector-Insights.svg","title":"Rural or regional health system","description":"Serving a wide catchment with long travel times."}];topics-data:[{"title":"Building the Business Case","description":"Evaluate the clinical,operational,and financial case for launching a CAR-T program.","url":"\/playbook\/building-the-business-case\/","accent":"dark"},{"title":"Reimbursement,Billing & Coding","description":"Navigate reimbursement requirements with practical guidance for community settings.","url":"\/playbook\/reimbursement-and-billing\/","accent":"blue"},{"title":"Quality","description":"Understand quality standards and regulatory considerations for CAR-T programs.","url":"\/playbook\/quality\/","accent":"blue"},{"title":"Operations & Infrastructure","description":"Plan the facilities,workflows,and operational capabilities needed to deliver CAR-T.","url":"\/playbook\/operations-and-infrastructure\/","accent":"blue"},{"title":"Contracting & Partnerships","description":"Build the relationships that support a successful community CAR-T program.","url":"\/playbook\/contracting-and-partnerships\/","accent":"pink"},{"title":"Managing Adverse Events","description":"Access practical guidance for recognizing and managing common CAR-T toxicities.","url":"\/playbook\/guidance-for-car-t-related-adverse-reactions\/","accent":"pink"},{"title":"Continuity & Shared Care","description":"Support patients throughout their CAR-T journey across care settings.","url":"\/playbook\/continuity-of-care\/","accent":"pink"},{"title":" Patient Selection & Support ","description":"Identify,refer and support eligible patients ","url":"\/playbook\/patient-selection-and-support\/","accent":"pink"}]}#-supreme-stats-4-6{stats-data:[{"number":"#1 unmet need","description":"Reimbursement and implementation guidance,per the CAR-T Vision survey"},{"number":"400+","description":"member organizations in ARM’s network"},{"number":"Developed with Community","description":"By people who’ve implemented CAR-T in community settings"}]}